X

Drug Profile

Research programme: cancer vaccines - RNAimmune/University of California

Alternative Names: RAS tumour vaccines - RNAimmune

Latest Information Update: 10 Feb 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator RNAimmune; University of California
Developer RNAimmune
Class Antineoplastics; Cancer vaccines; Immunotherapies; RNA vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Cancer

Most Recent Events

06 Feb 2023 Preclinical trials in Cancer (Prevention) in USA (unspecified route), before February 2023
06 Feb 2023 RNAimmune announces intention to submit IND to US FDA for Cancer
23 Apr 2021 Early research in Cancer (Prevention) in USA, prior to April 2021

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com